EWTX vs SLDB
EWTX: Edgewise Therapeutics develops precision small-molecule muscle modulators targeting rare neuromuscular and cardiac diseases, with sevasemten advancing in late-stage trials for Duchenne and Becker muscular dystrophies. SLDB: A gene therapy company advancing a pipeline of treatments for rare neuromuscular and cardiac diseases including Duchenne muscular dystrophy, Friedreich's ataxia, and cardiomyopathy.
Side-by-side fundamentals
| Metric | EWTX | SLDB | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $38.33 | $8.10 | |
| Market cap as of 2026-07-23 | $4.1B | $808M | |
| PEG as of 2026-07-23 | -3.27 | n/a | |
| Net margin as of 2026-07-23 | n/a | -588.3% | |
| Operating margin as of 2026-07-23 | n/a | -591.1% | |
| ROE as of 2026-07-23 | -32.6% | -74.5% | EWTX higher |
| ROA as of 2026-07-23 | -31.0% | -62.0% | EWTX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-23 | 0.31 | 2.40 | |
| 1-year return as of 2026-07-22 close | +195.6% | +32.8% | EWTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.